


How to bridge the gap between academia and industry
Shared interests, mutual gain, flexibility and trust are key to building win–win partnerships in drug development.

Connecting and engaging those who care about cancer
International oncology experts reunited as one oncology community to share the latest advances in the field at the ESMO annual meeting starting next week

A Virtual Train to ESMO travelling through 15 countries
With the “departure” of the virtual ESMO train in August, the ESMO Young Oncologists Committee (YOC) and the ESMO Climate Change Task Force are creating new opportunities for networking and sharing knowledge, while raising awareness on how climate change hits on cancer care

Virtual Plenary Debate, a new session not-to-be missed
Presented at the ESMO Virtual Plenaries this year, four key studies in oncology will animate the debate

CheckMate 743 reinforces the role of immunotherapy in first-line mesothelioma
Nearly 1 in 4 patients with pleural malignancy continue to benefit from nivolumab plus ipilimumab at 3 years

From empiric testing to rational design: two decades of progress in phase I trials
Ensuring equitable access to innovative treatments is now the major challenge in oncology, says Prof. Alex Adjei

Translating research ideas into patient benefits
Investigations are time-consuming and expensive, so greater public funding is needed, according to Prof. George Coukos

Precision oncology is the goal today, not a simple slogan
Prof. Lisa Licitra: “Truly pursuing precision medicine means pushing the boundaries of patient selection using molecular biology and artificial intelligence on all big data, not just molecular information”